SAN FRANCISCO — Treatment with brolucizumab resulted in visual acuity letter gains among patients with age-related macular degeneration and polypoidal choroidal vasculopathy, according to a presentation at Retina Subspecialty Day at the American Academy of Ophthalmology annual meeting.
“Most of you have heard that in the last week, brolucizumab (Beovu, Novartis) was approved by the FDA to treat neovascular AMD,” Glenn J. Jaffe, MD, Robert Machemer Professor of Ophthalmology and Chief of the Vitreoretinal Division at Duke Eye Center, said during his presentation. “We
Uncategorized